Compare SID & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SID | CERT |
|---|---|---|
| Founded | 1941 | 2008 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2002 | 2020 |
| Metric | SID | CERT |
|---|---|---|
| Price | $0.89 | $8.16 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $1.40 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 4.4M | 3.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $1.71 | $4.18 |
| Revenue Next Year | $1.58 | $5.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $0.84 | $4.45 |
| 52 Week High | $2.20 | $13.88 |
| Indicator | SID | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 37.56 | 63.71 |
| Support Level | $0.88 | $6.15 |
| Resistance Level | $1.06 | $8.39 |
| Average True Range (ATR) | 0.06 | 0.40 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 18.91 | 88.81 |
Companhia Siderurgica Nacional is an integrated steel producer. together with its subsidiaries operates in five main business segments: Steel industry: production and marketing of flat and long steels; Mining: extraction, processing and marketing of iron ore, tin, limestone and dolomite; Cement: production and commercialization of bagged and bulk cement, in addition to aggregates, concrete, and other related products; Energy: generation and sale of energy from almost all renewable sources; and Logistics: participations port concessions and fleets of road transport vehicles. The group generates the majority of its revenue from the Steel industry segment. Geographically, it derives a majority of revenue from Asia.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.